Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astri Therapeutics Inc (NQ: ATXS )

9.300 -0.290 (-3.02%)
Streaming Delayed Price Updated: 3:18 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Astri Therapeutics Inc

< Previous 1 2 3 Next >
Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Names Chris Morabito Chief Medical Officer
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
From Astria Therapeutics
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present STAR-0215 Data at the 2022 American Academy of Allergy, Asthma and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Investor Conferences
From Astria Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.